InnoCare Pharma’s application for marketing approval of Tancitumomab for injection
May 23, 2025
Source: drugdu
81
On May 21, InnoCare Pharma (688428/09969) announced that the company received a notice from the National Medical Products Administration that the application for the marketing approval of tafasitamab combined with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma was approved. This is the first CD19 monoclonal antibody approved in China to treat this disease, marking an important progress for the company in the field of hematological tumors.
The announcement mentioned that Tancitumomab is a monoclonal antibody targeting CD19 and is suitable for adult patients who are not suitable for autologous stem cell transplantation. In addition, Tancitumomab combined with lenalidomide has also been approved for the treatment of eligible patients in Hong Kong, Macau and Taiwan, China, showing its potential for application in multiple regions.
In the first quarter of 2025, InnoCare Pharma achieved revenue of 381 million yuan and net profit attributable to shareholders of the parent company of 17.97 million yuan.
https://finance.eastmoney.com/a/202505213410775926.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Lepu Medical’s Sodium Hyaluronate Solution for Injection is Approved for Registration to Expand Business in the Consumer Healthcare Field July 15, 2025
- Digene Pharmaceuticals’ Suvotinib Tablets are included in the latest version of the NCCN guidelines to create a new paradigm for the internationalization of China’s “original” new drugs July 15, 2025
- Ascentage Pharmaceuticals is out with its powerful weapon July 15, 2025
- $10 billion! Merck bets on respiratory drugs July 15, 2025
- Expected to increase performance by over 40% in the first half of the year, with employee stock ownership being the first to promote high-quality development July 15, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
